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Abstract (248 words) 
Introduction: Time to first seizure is a common outcome in antiepileptic drug (AED) 
studies. Previous studies have typically failed to find statistically significant differences 
between carbamazepine (CBZ) and valproate (VPS). We re-analysed a meta-analysis 
comparing CBZ and VPS monotherapy with new powerful statistical methods which 
incorporate baseline seizure rate information. 
Methods: Individual patient data were available on 1,265 patients from a meta-analysis 
of 5 trials. The outcome measure was time to first seizure after randomisation, adjusted 
for background variables and baseline seizure rate.  
Results: We found strong evidence of an interaction between treatment and epilepsy 
type, and between treatment and age. For generalized onset seizures VPS was 
statistically significantly better than CBZ: VPS delayed the first seizure after treatment 
58%, 52%, 44% and 36% longer than CBZ for individuals aged 10, 20, 30 or 40, 
respectively.  For partial onset seizures in individuals older than 30, CBZ was 
significantly better then VPS; CBZ delayed the time to first seizure by 9%, 25%, 44% 
and 66% longer than VPS for individuals aged 20, 30, 40 or 50, respectively. 
Discussion: The results show clear age-varying differences between the effectiveness of 
CBZ and VPS for generalized onset and partial onset seizures, which have not been 
identified in previous studies using standard statistical methods. In future trials of AED 
monotherapy or add-on where time to first or Nth seizure is an outcome, methodology 
which can incorporate baseline seizure rate information would allow more powerful 
comparisons between treatments or between treatment and placebo. 
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Introduction 
Antiepileptic drug (AED) treatment choices should be based upon reliable evidence 
derived primarily from randomized controlled trials (RCTs). Such trials should use 
appropriate methods of analysis. In this paper we present a new statistical model that 
uses baseline seizure counts in the statistical modelling of the outcome time to first 
seizure after randomization (Cowling et al., 2006). Time to first seizure is an outcome 
recommended by the International League against Epilepsy for monotherapy trials 
(International League Against Epilepsy Commission on Antiepileptic Drugs, 1998), and 
is also being advocated as an outcome for add-on therapy trials.  
 
We examine data on a large cohort of epilepsy patients from a meta-analysis of RCTs 
comparing carbamazepine (CBZ) and valproate (VPS) monotherapy, which are 
recommended as first line treatments (Scottish Intercollegiate Guidelines Network., 
2003, Wallace, 1997) despite uncertainty about their relative effects. A reanalysis of 
these data using our new methodology (Cowling et al., 2006) has detected clinically 
important differences between CBZ and VPS that were not detected in a previous meta-
analysis of these data (Marson et al., 2002). Furthermore, the new methodology allows 
appropriate estimation of effects even though the assumptions of the proportional 
hazards model are not met. The new methodology, the results and their interpretation 
are presented for a clinical readership. 
 
Subjects and Methods 
We analysed data on 1,265 individuals from five clinical trials comparing CBZ with 
VPS monotherapy in children and adults (de Silva et al., 1996, Heller et al., 1995, 
Mattson et al., 1992, Richens et al., 1994, Verity et al., 1995). Forty patients with 
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inadequate information on post-randomization seizures could not be included in the 
analyses, and a further 39 patients with unknown pre-randomization seizure counts and 
three with unknown ages were excluded, leaving 1,183 (94%) patients with complete 
data. Sensitivity analyses showed that 12 (1%) individuals with very high (>200) 6-
month pre-randomization seizure counts were overly influential on the results, and these 
individuals were excluded leaving 1171 individuals for analysis.  
 
The outcome of interest was the time from randomization to a first seizure. A typical 
analysis might use a Cox proportional hazards model, which would assume that the risk 
of first seizure on CBZ and VPS are proportional, that is have the same ratio at all times, 
and would adjust for the 6-month pre-randomization seizure count as an important 
explanatory variable. However the assumption of proportional hazards is not satisfied in 
these data (Kwong and Hutton, 2003). In contrast, accelerated failure time models, 
which assume instead that the times to first seizure are proportional, have been found to 
fit these data well (Kwong and Hutton, 2003). Accelerated failure time models assume 
that the times to event (rather than the risk) are themselves proportional, so that one 
group has proportionally accelerated times to event compared to baseline. 
 
We have developed methodology to allow appropriately for the uncertainty in observed 
seizure counts (Cowling et al., 2006). The model is represented graphically in Figure 1, 
where the arrows indicate that both the pre-treatment seizure count and post-treatment 
time to first seizure depend on unobserved seizure rates, therefore both of these 
variables are outcomes, or dependent, variables. Conventional analyses using 
proportional hazards and accelerated failure time models would allow the post-treatment 
time to be predicted by the observed pre-treatment count, whereas our model specifies 
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that both are predicted by (unobserved) seizure rates. Our model allows for seizure rates 
to vary depending on baseline characteristics including age, sex, epilepsy type and trial 
(Figure 1). Under the new model, each patient was assumed to have a constant 
underlying seizure rate before the initiation of anti-epileptic therapy. Our model further 
specifies that each patient’s post-therapy underlying seizure rate was reduced relative to 
the baseline rate, with a greater reduction in seizure rate resulting in a longer 
(decelerated) time to first post-randomization seizure, which indicates a better therapy. 
The degree of acceleration or deceleration in the time to first seizure can be obtained 
from the estimated regression coefficients and is usually referred to as the ‘acceleration 
factor’. Using outcome data on the pre-treatment seizure count and the post-treatment 
time to first seizure, we estimate the relative importance of the background information 
and the treatment administered on the reduction in seizure rate due to therapy. Therefore 
our model estimates not only the effects of background information on the baseline 
seizure rate but also the effects of both background and treatment effects on the change 
in seizure rate due to therapy. A further advantage of the new methodology is that it 
incorporates uncertainty in the (unobserved) baseline seizure count, whereas a typical 
proportional hazards model would include the seizure count as a proxy for baseline rate 
ignoring the uncertainty. 
 
Both the number of seizures recorded in the 6 months prior to randomization, and the 
time to first seizure after randomization are outcome (‘dependent’) variables in the new 
methodology. The explanatory (‘independent’) variables used included age, sex, trial, 
and seizure type (generalized-onset or partial-onset). Seizures were classified as 
generalized or partial-onset by the original trialists using the International League 
Against Epilepsy Classification of seizures. 
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We investigated the goodness of fit of the model by plots of the residuals. To explore 
the influence of the patients with high seizure rates (>100 and >50 in 6 months) on the 
results, we conducted sensitivity analyses by excluding these patients. We performed all 
analyses using R version 2.1.0 (The R Foundation for Statistical Computing, Vienna). 
Further technical details may be found in (Cowling et al., 2006). 
 
Results 
Of the 1171 patients included in the analyses, 784 (384 CBZ and 400 VPS) individuals, 
of whom 570 (73%) were males, had their seizures classified by the original trialists as 
partial onset seizures including simple partial, complex partial and secondary 
generalized tonic clonic seizures. The remaining 387 (197 CBZ and 190 VPS) 
individuals, including 193 (50%) males, had seizures classified by the original trialists 
as generalized onset seizures, all of whom had tonic clonic seizures. Although some 
patients may have had other generalized seizure types such as absence or myoclonus, 
only tonic clonic seizures were recorded during follow-up and baseline and results apply 
to tonic clonic seizures only. Individuals with generalized onset seizures had median 3 
(interquartile range (IQR): 2, 4) seizures in the 6 months prior to randomization, while 
individuals with partial onset seizures had median 4 (IQR: 2, 7) seizures. The Kaplan-
Meier estimates of the time to first seizure are shown in Figure 2, without adjusting for 
pre-randomization seizure rates. For generalized-onset tonic clonic seizures, the median 
time to first seizure after randomization was 321 days in the CBZ arm and 339 days in 
the VPS arm. For partial-onset seizures, the median times to first seizure after 
randomization were 116 days and 56 days in the CBZ and VPS arms, respectively. 
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When fitting the new model to the epilepsy data, we found no effect of gender on the 
underlying seizure rate or as an effect modifier on the reduction in seizure rate by the 
treatments, so omitted this variable. Age and seizure type (partial versus generalized 
onset) were both important in explaining the variability in seizure rates between 
individuals, and both modified the effect of the treatments. Seizure rates were also 
adjusted for the effects of study. 
 
The results of a gamma accelerated failure time model are shown in Table 1, and 
contrasted with the estimated regression coefficients of the new model. Under the 
gamma model, which has previously been shown to fit these data well (Kwong and 
Hutton, 2003), VPS was superior for generalized onset seizures in children and young 
adults, while CBZ was superior for partial onset seizures (Table 1), however the gamma 
model did not have the power to detect statistically significant differences. Under the 
new model, younger individuals and those with partial-onset epilepsies had typically 
higher baseline seizure rates, and they benefited from a higher reduction in seizure rate 
after treatment (Table 1). The interactions between treatment and epilepsy type, and 
treatment and age, were both highly statistically significant. Comparing regression 
coefficients reveals that the new method finds a substantial benefit for VPS in 
generalized onset seizures, and a benefit for CBZ in older patients with partial onset 
seizures. The regression coefficients of the gamma model and the new methodology 
may be directly compared, and Table 1 shows that the estimated effects are of similar 
direction and magnitude under both models. For example, patients with partial-onset 
seizures had higher seizure rates than those with generalized-onset seizures, as shown 
by the regression coefficient of 0.700 under the gamma model, whereas patients with 
partial-onset seizures had much higher baseline seizure rates (regression coefficient 
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1.304) which were attenuated but still higher than patients with generalized-onset 
seizures after treatment (1.304 – 0.787 = 0.517) under the new model. Residual 
differences between these estimates of the effects of seizure type are likely accounted 
for in the differences between the estimated effects of age, given the high degree of 
correlation between age and seizure type (12). The increased statistical power of the 
new methodology is also apparent from the smaller p-values for similar effect sizes 
(Table 1). 
 
To aid interpretation of the new model, the regression coefficients for the treatment 
effect and interaction terms may be presented as acceleration factors (AF) for CBZ vs 
VPS, which are the relative acceleration (<1) or deceleration (>1) in time to first seizure 
for individuals treated with CBZ rather than VPS (Table 2). The results show that the 
median time to first seizure for a patient aged 10 with generalized onset seizures would 
be 58% shorter (AF=0.42) if CBZ were assigned rather than VPS. In contrast, the 
median time to first seizure for a patient aged 40 with partial onset seizures would be 
44% longer (AF=1.44) for CBZ compared to VPS. These estimates are consistent with 
the empirical patterns in time to first seizure shown in Figure 2. 
 
We examined residual plots and found that the fit of the model was satisfactory. 
Sensitivity analyses showed that the relative effects of the treatments were not changed 
if 49 patients with more than 50 seizures or 11 patients with more than 100 seizures in 
the 6 months prior to randomization were excluded (appendix table). 
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Discussion 
The results show a clear preference for VPS over CBZ for all patients with generalized 
onset tonic clonic seizures. Conversely, the results support the use of CBZ rather than 
VPS for most patients with partial onset seizures. It is unclear, however, which is the 
best treatment for patients under the age of 30 with partial-onset seizures. The results 
show a strong dependence of time to first seizure on prior seizure rates, age, and 
epilepsy type.  While the Kaplan-Meier estimates of time to first seizure were initially 
similar for generalized-onset epilepsies, the curves later diverge showing a clear 
advantage of VPS (Figure 2).  After adjusting for prior seizure rates, age, and epilepsy 
type, the new methodology estimates that VPS can approximately double the expected 
time to first seizure for a typical patient aged 20, compared to CBZ (Table 2). In 
contrast for partial-onset epilepsies the Kaplan-Meier estimates of time to first seizure 
showed a clear advantage of CBZ (Figure 2), and after adjusting for prior seizure rates, 
age, and epilepsy type, the new methodology estimates that CBZ can increase by 44% 
the expected time to first seizure for a typical patient aged 40, compared to VPS (Table 
2). 
 
A potential limitation of our study is the assumption of constant seizure rate, since 
seizures can occur in clusters. A moderate degree of clustering would result in a 
typically longer time to first post-randomization seizure than predicted by our model 
(except for a few patients in the midst of a cluster of seizures at randomization, who 
would have much shorter times to first seizure than predicted), and the absolute 
reduction in seizure frequency estimated by our model would be slightly optimistic. 
However, the relative differences between CBZ and VPS (Table 2) should be 
maintained even under clustering, because of the randomization of treatments. Without 
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data on the dates of each seizure it is impossible for us to assess or allow for clustering 
in these data, and we would recommend that future trials record the precise dates of 
seizures before and after randomization. A caveat of the new methodology is that the 
estimated regression coefficients can be somewhat sensitive to outlying values; we 
found that a small number of patients with very high baseline seizure counts could be 
influential to the results. Therefore we recommend that care should be taken when 
applying the new methodology, and in particular the influence of outliers should be 
investigated. 
 
A further limitation in our study is the quality of data. While our data contain the 
standardized outcome of seizures in the 6 months prior to randomisation, the original 
trialists collected some data in different formats (i.e. time from first seizure to 
randomisation and number of seizures in this period) before the data were converted to a 
consistent format for the meta analysis (Marson et al., 2002). Extrapolation or 
interpolation of these data to the standardised outcome used in our study may have 
biased the estimated treatment effects, although randomization should have attenuated 
this bias somewhat. We note that in our model it is straightforward to incorporate data 
on time from first seizure to randomisation when these are available. A separate issue 
with the data quality concerns the classification of epilepsy type by the original trialists, 
since further analysis (Williamson et al., 2002) has suggested that misclassification may 
have affected the results, particularly inflating the treatment-age interaction since age is 
a proxy for epilepsy type.  
 
It should also be noted that time to first seizure is only one of the recommended 
outcomes for assessing the efficacy of AEDs (International League Against Epilepsy 
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Commission on Antiepileptic Drugs, 1998). In particular, consideration of safety 
profiles is important. 
 
In future AED trials, methodology which can incorporate baseline seizure rate 
information would allow more powerful comparisons between treatments. The example 
chosen in this paper included data from comparative monotherapy trials, and illustrates 
increased statistical power compared to standard statistical analyses. This approach 
would also be valid for regulatory add-on trials in which a new drug or placebo is added 
to a stable base of other AEDs. Some are advocating trials using time to first seizures to 
screen for effective drugs, and the methods outlined in this paper would help maximise 
the power of such studies.  
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Table 1. Estimated regression coefficients under the gamma accelerated failure 
time model and the new methodology. 
Factora gamma model New methodology 
   Baseline seizure rate Difference in rate 
after treatment 
 Regression 
coefficientb 
p-
value
Regression 
coefficientc
p-
value
Regression 
coefficientd 
p-
value
CBZ reference reference reference 
VPS -0.622 0.288 - - -1.007 <0.001
   
Generalized-
onset epilepsy 
reference reference reference 
Partial-onset 
epilepsy 
0.700 0.007 1.304 <0.001 -0.787 <0.001
   
 Age at 
randomization 
(in decades) 
-0.248 <0.001 -0.012 0.592 0.074 0.008
   
 Log(number of 
seizures) 
0.501 <0.001 - - - -
   
VPS * partial-
onset epilepsy 
0.471 0.167 - - 0.815 <0.001
VPS * age (in 0.175 0.032 - - 0.139 <0.001
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decades) 
 
a  All models are also adjusted for study effects. 
b A regression coefficient >0 (<0) would indicate a quicker (slower) time to first seizure 
relative to the reference group. 
c  A regression coefficient >0 (<0) would indicate an increased (decreased) pre-
treatment seizure rate relative to the pre-treatment seizure rate in the reference group. 
d  A regression coefficient >0 (<0) would indicate an increased (decreased) post-
treatment seizure rate, relative to the post-treatment seizure rate in the reference group. 
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Table 2. Predicted relative changes (acceleration factors) in time to first seizure for 
individuals with different ages and epilepsy type, assigned to treatment with 
carbamazepine (CBZ) compared to sodium valproate (VPS). 
Age Generalized onset Partial onset 
 Acceleration 
factor (AF)a 
95% CI for AF Acceleration 
factor (AF)a
95% CI for AF 
Age 10b 0.420c (0.331, 0.533)    
Age 20 0.483 (0.371, 0.629) 1.090 (0.912, 1.303) 
Age 30 0.555 (0.416, 0.740) 1.253 (1.034, 1.518) 
Age 40 0.638 (0.467, 0.870) 1.440 (1.174, 1.767) 
Age 50b    1.655 (1.333, 2.055) 
 
a An acceleration factor <1 would indicate an accelerated, i.e. shorter, time to first 
seizure for patients taking CBZ rather than VPS. 
b Predictions are not made for individuals aged 50 with generalized onset epilepsies, or 
aged 10 with partial onset epilepsies, since the data contained few such individuals. 
c The proportional change in seizure rate on VPS vs CBZ (which is equivalent to the 
acceleration factor in time to first seizure on CBZ vs VPS) for an individual with 
generalized-onset seizures and aged 10 can be calculated from the coefficients in Table 
1 via exp(-1.007+0.139) = 0.420.
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Figure 1. A model for epilepsy data showing how data on pre-treatment seizure counts 
may be incorporated to allow more precise estimation of the effect of anti-epileptic 
therapy in reducing the pre-treatment seizure rate. Traditional analyses would include 
the pre-treatment count as an independent variable rather than as a second dependent 
variable. 
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Figure 2. Time to first seizure by epilepsy type and treatment. 
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Appendix table: Sensitivity analysis of results of joint model to the exclusion of individuals with high seizure counts. The results for individuals 
with ≤200 seizures have been selected for presentation in Table 2. 
Inclusion N  Generalized onset seizures 
criteria   Age 10  Age 20  Age 30  Age 40 
   AF 95% CI for AF  AF 95% CI for AF  AF 95% CI for AF  AF 95% CI for AF 
All data 1183  0.079 (0.065, 0.096)  0.098 (0.077, 0.125)  0.123 (0.093, 0.162)  0.153 (0.112, 0.209) 
≤200 seizures 1171  0.420 (0.331, 0.533)  0.483 (0.371, 0.629)  0.555 (0.416, 0.740)  0.638 (0.467, 0.870) 
≤100 seizures 1160  0.459 (0.367, 0.573)  0.524 (0.405, 0.678)  0.599 (0.448, 0.800)  0.684 (0.497, 0.941) 
≤50 seizures 1122  0.498 (0.406, 0.610)  0.556 (0.433, 0.715)  0.622 (0.465, 0.830)  0.694 (0.502, 0.960) 
   Partial onset seizures 
   Age 20  Age 30  Age 40  Age 50 
   AF 95% CI for AF  AF 95% CI for AF  AF 95% CI for AF  AF 95% CI for AF 
All data 1183  1.186 (0.994, 1.417)  1.479 (1.224, 1.787)  1.844 (1.509, 2.253)  2.298 (1.861, 2.838) 
≤200 seizures 1171  1.090 (0.912, 1.303)  1.253 (1.034, 1.518)  1.440 (1.174, 1.767)  1.655 (1.333, 2.055) 
≤100 seizures 1160  1.319 (1.095, 1.589)  1.508 (1.240, 1.833)  1.723 (1.405, 2.113)  1.968 (1.592, 2.434) 
≤50 seizures 1122  1.626 (1.329, 1.990)  1.817 (1.480, 2.231)  2.030 (1.648, 2.501)  2.268 (1.835, 2.803) 
 
 
 
